AdnaGen's diagnostics detect circulating tumor cells in tumor patients. Because tumor cells survive only hours in the bloodstream, there must be an active source, e.g. a relapse or a metastasis. Therefore, the presence of circulating tumor cells is an unfavorable indicator for the progress of the tumor disease.

AdnaGen's proprietary 'combination-of-combinations-principle' allows the reliable and very sensitive detection of circulating tumor cells and meets the following medical challenges:

• Improved tumor treatment through real time monitoring of therapy success
• Early detection of metastases or relapses
• Provision of an additional independent prognostic factor for staging
• Patient stratification
• Efficient drug development

Last update: October, 15, 2008